Om Research LLC | Lancaster, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug's effects on blood tests and other tests related to PSC disease activity.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria :
Exclusion Criteria :
Primary purpose
Allocation
Interventional model
Masking
68 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Ipsen Clinical Study Enquiries
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal